PeterTadrosMDFACC
Cardiology • Kansas City, KSEchocardiography, Interventional Cardiology
University of Kansas Health System
Dr. Tadros is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
Ste G600
Kansas City, KS 66160Phone+1 913-588-9601Fax+1 913-588-9770
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Cardiovascular Disease, 1994 - 1999
University of MinnesotaResidency, Internal Medicine, 1990 - 1993- University of MinnesotaResidency, Internal Medicine, 1993
McGovern Medical School at UTHealthClass of 1990- Washington University/B-JH/SLCH ConsortiumFellowship, Cardiovascular Disease
- Washington University/B-JH/SLCH ConsortiumFellowship, Interventional Cardiology
Certifications & Licensure
MO State Medical License 1994 - 2026
CO State Medical License 2003 - 2025
KS State Medical License 1999 - 2025
OH State Medical License 1999 - 2011
TX State Medical License 1991 - 2009
American Board of Internal Medicine Cardiovascular Disease- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- Fellow SCAI
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement Start of enrollment: 2010 Dec 10
- Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
- Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsTricuspid Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: 1-Year Outcomes From the TRILUMINATE Randomized Cohort.Gilbert H L Tang, Rebecca T Hahn, Brian K Whisenant, Nadira Hamid, Hursh Naik
Journal of the American College of Cardiology. 2025-01-28 - Tricuspid Transcatheter Edge-to-Edge Repair in Patients With Transvalvular CIED Leads: The TRILUMINATE Pivotal Trial.Hursh Naik, Matthew J Price, Samir Kapadia, Brian K Whisenant, Peter Tadros
JACC. Clinical Electrophysiology. 2025-01-20 - Nationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study.Rhythm Vasudeva, Harsh Mehta, Wan-Chi Chan, Sania Jiwani, Sri G Yarlagadda
Annals of Translational Medicine. 2024-12-24
Press Mentions
His Only Hope After Heart AttackMay 11th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
